Meet Dr. Morse at Duke

Michael A. Morse, MD, MHS
Department: Medicine
Division: Medical Oncology

Training:
M.D., Yale University School of Medicine, Connecticut, 1990

Residency:
Internal Medicine, University of Washington, 1990-93
Hematology/Oncology, Duke University Medical Center, North Carolina, 1993-96
Other Degrees:
M.H.S., Duke University Medical Center, North Carolina, 2000

Clinical Interests:Gastrointestinal malignancies, hepatic tumors, immunotherapy
Research Interests:We are studying the use of immune therapies to treat various cancers, including gastrointestinal, breast, and lung cancers and melanoma. These therapies include vaccines based on dendritic cells developed in our laboratory as well as vaccines based on peptides, viral vectors, and DNA plasmids. Our group is also a national leader in the development and use of laboratory assays for demonstrating immunologic responses to cancer vaccines. Finally, we are developing immunotherapies based on adoptive transfer of tumor and viral antigen-specific T cells.

Our current clinical trials include phase I and II studies of immunotherapy for: patients with metastatic malignancies expressing CEA, high risk resected malignancies such as breast, colon, and lung cancer. We are performing a clinical trial of adoptive transfer of CMV specific T cells in conjunction with the BMT program.

My clinical area of expertise is in gastrointestinal oncology, in particular, the treatment of hepatic malignancies, and malignant melanoma.

For more information, see http://arcadia.mc.duke.edu/LyerlyLab/body_index.html

Key words: dendritic cells, immunotherapy, vaccines, T cells, gastrointestinal oncology, melanoma, hepatoma